DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

NexLife vs SkinnyRx: November 2026 prices compared

As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; SkinnyRx shows only no tirzepatide price, so no like-for-like comparison is possible.

Released · Last reviewed · how we verify

On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; SkinnyRx shows only no semaglutide price, so no like-for-like comparison is possible.

NexLife and SkinnyRx, measure by measure

NexLife and SkinnyRx side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureNexLifeSkinnyRx
Tirzepatide, month to month$129 (per month)—
Tirzepatide, lowest printed$115 (12-month plan)—
Semaglutide, month to month$109 (per month)—
Semaglutide, lowest printed$95 (12-month plan)—
Dose pricingsame price at every dosepriced by dose or not stated
Membership or program feenonenot confirmed
Computed score33.6 of 40 (position 4 of 27)0 of 40 (position 21 of 27)
FDA warning letters730096 (2026-06-08)717989 (2026-02-20)
November 20 readfirst-party readfirst-party read, changed

Strengths and limitations: which fits whom

NexLife prints one price at every dose with no membership, so a dose increase does not change the bill. SkinnyRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

Regulatory record

FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 717989 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to SkinnyRx; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check SkinnyRx’s current prices ↗

Frequently asked

Which is cheaper, NexLife or SkinnyRx?

On compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; SkinnyRx shows only no tirzepatide price, so no like-for-like comparison is possible. On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; SkinnyRx shows only no semaglutide price, so no like-for-like comparison is possible.

Do NexLife and SkinnyRx charge a membership fee?

NexLife: no membership fee; SkinnyRx: not confirmed on November 20, 2026. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are NexLife and SkinnyRx medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

NexLife recordNexLife alternativesSkinnyRx recordSkinnyRx alternativesAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.